Search PubMed⌕ Search

Biomedical subjects

Chul W Ahn

Publications and source records attributed to Chul W Ahn.

7 recordsLinked to original sources
PubMed2006

Changing spectrum of the diffuse infiltrative lymphocytosis syndrome.

OBJECTIVE: To describe the changing clinical spectrum of patients with diffuse infiltrative lymphocytosis syndrome (DILS) after the introduction of highly active antiretroviral treatment (HAART), and to carry out HLA class II oligotyping in these patients. METHODS: A retrospective chart review of patients with DILS who were referred to an outpatient facility for human immunodeficiency virus (HIV)-positive individuals between 1994 and 2003 was performed. DILS was diagnosed as suggested by previous criteria. Demographic features and relevant clinical, laboratory, and radiologic data were recorded and results analyzed. RESULTS: A total of 129 patients with DILS were identified. Of them, 56 (43%) were African American, 41 (32%) were white, and 32 (25%) were Hispanic. Parotid gland swelling appeared to be the sine qua non of DILS. Twenty-seven percent of patients had opportunistic infections. The status of 103 patients was available as of December 2003: 26 (25%) had died, of which only 6 (6%) succumbed to opportunistic infections. The prevalence of DILS had significantly decreased in the post-HAART era (1998 onwards) compared with that of the pre-HAART period (P < 0.000001). The prevalence of lymphocytic interstitial pneumonitis had also dropped significantly following introduction of HAART therapy (P = 0.015). A higher frequency of certain HLA class II alleles (DRB1) was found in African Americans with DILS compared with those with HIV without DILS (P = 0.006). CONCLUSION: The epidemiology, clinical presentation, and certain extraglandular manifestations of DILS have changed, concomitant with the introduction of HAART, further suggesting that DILS is an antigen (viral)-driven response and the primary treatment for it is anti-HIV therapy.

AIDS-Related Opportunistic Infections↗
PubMed2005

Sample size for a two-group comparison of repeated binary measurements using GEE.

Controlled clinical trials often randomize subjects to two treatment groups and repeatedly evaluate them at baseline and intervals across a treatment period of fixed duration. A popular primary objective in these trials is to compare the change rates in the repeated measurements between treatment groups. Repeated measurements usually involve missing data and a serial correlation within each subject. The generalized estimating equation (GEE) method has been widely used to fit the time trend in repeated measurements because of its robustness to random missing and mispecification of the true correlation structure. In this paper, we propose a closed form sample size formula for comparing the change rates of binary repeated measurements using GEE for a two-group comparison. The sample size formula is derived incorporating missing patterns, such as independent missing and monotone missing, and correlation structures, such as AR(1) model. We also propose an algorithm to generate correlated binary data with arbitrary marginal means and a Markov dependency and use it in simulation studies.

Algorithms↗
PubMed2005

Exact tests for one sample correlated binary data.

In this paper we developed exact tests for one sample correlated binary data whose cluster sizes are at most two. Although significant progress has been made in the development and implementation of the exact tests for uncorrelated data, exact tests for correlated data are rare. Lack of a tractable likelihood function has made it difficult to develop exact tests for correlated binary data. However, when cluster sizes of binary data are at most two, only three parameters are needed to characterize the problem. One parameter is fixed under the null hypothesis, while the other two parameters can be removed by both conditional and unconditional approaches, respectively, to construct exact tests. We compared the exact and asymptotic p-values in several cases. The proposed method is applied to real-life data.

Anti-Bacterial Agents↗
PubMed2005

Plasma uric acid levels in women with cervical intraepithelial neoplasia.

The objective of this study was to determine the association of plasma levels of uric acid, an endogenous antioxidant, in women with cervical intraepithelial neoplasia (CIN), while controlling for the confounding effects of human papillomavirus (HPV) infection, age, smoking, and use of oral contraception. Plasma-reduced and oxidized uric acid levels were determined in 650 women by high-performance liquid chromatography, employing electrochemical technique. The findings demonstrated that 1) plasma-reduced uric acid (PRUA) levels in women with CIN (n = 311) were significantly lower (P < 0.05) compared with women in a control group (n = 339); 2) according to multiple logistic regression analysis, PRUA levels were negatively (P = 0.0113) and HPV infection were positively associated (P < 0.0001) with CIN, after controlling for the confounding effects of the studied factors; 3) according to multiple regression analysis, there was a 31% decrease in CIN risk for each incremental increase of 1mg/dl of PRUA; and 4) according to polychotomous logistic regression analysis, independent of HPV infection, PRUA level was inversely associated with the histopathological graded severity of CIN. We have previously reported decreased plasma levels of exogenous antioxidants, for example, vitamins C and E, in women with CIN independent of HPV infection. The data suggest that plasma deficiencies of several antioxidants in HPV-infected uterine cervical tissue may create an oxidative environment that renders the tissue susceptible to free radical damage. It may be speculated that chronic free radical-induced tissue damage in the context of persistent HPV infection may be involved in the pathogenesis of CIN.

Adult↗
PubMed2003

An evaluation of methods for the stratified analysis of clustered binary data in community intervention trials.

A simulation study is conducted in a community intervention setting. Several methods of stratified analysis of clustered binary data are compared in terms of empirical significance and empirical power levels. They are the Mantel-Haenszel test statistic (chi(2) (MH)), the adjusted Mantel-Haenszel test statistic of Donald-Donner (chi(2) (DD)), Rao-Scott (chi(2) (RSN) and chi(2) (RSP)), and Zhang-Boos (chi(2) (ZBN) and chi(2) (ZBP)), Wald (chi(2) (W)), robust Wald (chi(2) (RW)), score (chi(2) (S)), robust score (chi(2) (RS)), and the test statistic based on generalized linear mixed model (GLMM) (chi(2) (GLMM)). When rho not equal 0, chi(2) (MH) has inflated type I error, and it should not be used when observations are correlated. The results also warn of the use of chi(2) (RSN) and chi(2) (RW) due to their poor performance in terms of empirical significance level. chi(2) (ZBP) and chi(2) (GLMM) have better empirical significance levels as compared to other statistics; however, chi(2) (ZBP) tends to have lower empirical powers than other statistics when the number of clusters (N) is less than 24. chi(2) (RSP) provides the highest empirical powers when rho > or = 0.1 and N < or = 12. When rho < or = 0.01, we recommend the use of chi(2) (RS) and chi(2) (GLMM) since they have better overall performance in terms of empirical significance levels and empirical power levels.

Adolescent↗
PubMedDate not supplied

Clonidine reduces diarrhea and sodium loss in patients with proximal jejunostomy: a controlled study.

BACKGROUND: Patients with short bowel syndrome have significant fluid losses. This represents a significant management problem, especially in patients with minimal residual intestine. We determined whether clonidine, an alpha2-adrenergic agonist, is effective in decreasing fecal water and sodium (Na) losses in patients with proximal jejunostomy. Eight parenteral nutrition (PN)-dependent subjects (3 men, 5 women), aged 49.9+/-10.2 years, with a residual small bowel length of 71.8+/-152.0 cm that ended in a jejunostomy, were studied. METHODS: Subjects were admitted to the North-western General Clinical Research Center (GCRC) for a 2-day equilibrium period while receiving a self-selected 100 g fat diet with protein 1.5 g/kg/d and 30 kcal/kg/d and 1 L/d of oral rehydration solution. A D-xylose test was performed after an overnight fast. On days 3-5, all stool and urine were collected for volume, weight, fat, nitrogen, energy, sodium, magnesium, potassium, and calcium. Meals were provided in duplicate and the equivalent portions consumed by each patient were analyzed for fluid volume, fat, nitrogen, energy, sodium, magnesium, calcium, and potassium in order to calculate nutrient balances. At the conclusion of the stool and urine collections (day 6), a clonidine (0.3 mg) patch was applied to the shoulder. Subjects were restudied after 1 week. RESULTS: Daily fecal volume and weight were 4.514+/-1.769 L/d and 4394+/-1727 g/d, respectively, at baseline. Five subjects were net "secretors" in that excreted fecal volume exceeded oral intake. Fecal volume decreased by 427+/-562 mL/d (8.9%, p=.07). Fecal weight decreased by 438+/-527 g/d (9.4%, p=.05). Urine volume correspondingly increased by 747+/-1934 mL (18.9%, p=not significant [NS]). The increase in urine output was weakly and negatively correlated with the decrease in fecal volume and weight (r=-0.37 and -0.41, respectively, p=NS). Oral fluid intake decreased slightly from 3.328+/-1.246 L/d baseline to 3.203+/-1.119 L/d with clonidine therapy (-3.8%, p=NS). Fecal Na loss was significantly decreased from baseline (887+/-996 mg/d, 11.2+/-12.3%; p=.036). This was not related to decreased oral Na intake, which actually increased from baseline (3.799+/-2.271 g/d) to 3.933+/-1.314 g/d after clonidine therapy (p=NS). No patient developed hypotension. CONCLUSIONS: Our results show the transdermal administration of clonidine is associated with a modest but clinically significant decrease in fecal output in patients with short bowel syndrome and high-output proximal jejunostomy that require chronic parenteral fluid infusion. This is accompanied by decreased fecal Na loss.

Administration, Cutaneous↗